Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-22. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Celebrations and anniversaries === On 21 November 1989, Crosby, Stills & Nash performed the song "Chippin' Away" from Graham Nash's 1986 solo album Innocent Eyes in front of the Brandenburg Gate. On 25 December 1989, Leonard Bernstein gave a concert in Berlin celebrating the end of the Wall, including Beethoven's 9th symphony (Ode to Joy) with the word "Joy" (Freude) changed to "Freedom" (Freiheit) in the lyrics sung. The poet Schiller may have originally written "Freedom" and changed it to "Joy" out of fear. The orchestra and choir were drawn from both East and West Germany, as well as the United Kingdom, France, the Soviet Union, and the United States. On New Year's Eve 1989, David Hasselhoff performed his song "Looking for Freedom" while standing atop the partly demolished Wall in front of 200,000 people. Roger Waters performed the Pink Floyd album The Wall just north of Potsdamer Platz on 21 July 1990, with guests including Scorpions, Bryan Adams, Sinéad O'Connor, Cyndi Lauper, Thomas Dolby, Joni Mitchell, Marianne Faithfull, Levon Helm, Rick Danko and Van Morrison. Over the years, there has been a repeated controversial debate as to whether 9 November would make a suitable German national holiday, often initiated by former members of political opposition in East Germany, such as Werner Schulz. Besides being the emotional apogee of East Germany's peaceful revolution, 9 November is also the date of the 1918 abdication of Kaiser Wilhelm II and declaration of the Weimar Republic, the first German republic.
==== Civil Protection ==== The Civil Protection is the Combine's primary law enforcement agency on Earth, whose ranks are drawn from unmodified, volunteering humans. Commonly referred to as "metrocops" or "CPs", Civil Protection personnel wear light body armor and face masks which resemble a modified PMK gas mask. They also have voice modifiers, masking their normal voices. They typically carry electroshock batons (named stun-sticks in the game) and pistols, and are occasionally equipped with submachine guns. The Civil Protection are frequently brutal in their methods, keeping the local populace in line via intimidation and violence. Interrogations, inspections, raids, random beatings, summary executions and acts of police brutality are all used as a means of policing their jurisdictions; the Civil Protection's methods are justified by their role as "protectors of the civilians' well-being". On the outskirts of City 17, the Civil Protection carry out constant patrols for escapees from the city. Civil Protection personnel are in constant contact with the Combine's Overwatch headquarters, which issues them objectives and situation updates. Upon the death of Civil Protection personnel, their armor detects that its wearer is no longer alive and automatically informs the Overwatch of the fatality.
=== Muscle mass === Researchers are still debating whether the more noticeable muscles are larger in size as well. It should be clarified, though, that muscle mass is not the same as muscle strength. Some say that human growth hormone will build muscle mass through raised insulin-like growth factors levels leading to heightened protein synthesis without any side effects while other researchers argue that there have been no such findings on young healthy adults. The second argument is more supported by research discoveries that HGH affects muscle protein synthesis no differently than a placebo does.
Sources: en.wikipedia.org
=== Since Silk Road === From late 2013 through to 2014, new markets started launching with regularity, such as the Silk Road 2.0, run by the former Silk Road site administrators, as well as the Agora marketplace. Such launches were not always a success; in February 2014 Utopia, the highly anticipated market based on Black Market Reloaded, opened only to shut down eight days later following rapid actions by Dutch law enforcement. February 2014 also marked the short lifespans of Black Goblin Market and CannabisRoad, two sites which closed after being deanonymized without much effort. November 2014 briefly shook the darknet market ecosystem, when Operation Onymous, executed by the United States' FBI and UK's National Crime Agency, led to the seizure of 27 hidden sites, including Silk Road 2.0, one of the largest markets at the time, as well 12 smaller markets and individual vendor sites. By September 2014, Agora was reported to be the largest market, avoiding Operation Onymous; as of April 2015, Agora has gone on to be the largest overall marketplace, with more listings than the Silk Road at its height. Further market diversification occurred in 2015, as did further developments around escrow and decentralization. In March 2015, the Evolution marketplace performed an "exit scam", stealing escrowed bitcoins worth $12 million, half of the ecosystem's listing market share at that time. The closure of Evolution led to users redistributing to Black Bank and Agora.
=== Supported enzymes and peptides === Enzymes, proteins, and other biologically and chemically active substances have been immobilized on magnetic nanoparticles. The immobilization of enzymes on inexpensive, non-toxic and easily synthesized iron magnetic nanoparticles (MNP) has shown great promise due to more stable proteins, better product yield, ease of protein purification and multiple usage as a result of their magnetic susceptibility. They are of interest as possible supports for solid phase synthesis. This technology is potentially relevant to cellular labelling/cell separation, detoxification of biological fluids, tissue repair, drug delivery, magnetic resonance imaging, hyperthermia and magnetofection. Random versus site-directed enzyme immobilization Enzymes immobilized on magnetic nanoparticles (MNP) via random multipoint attachment, result in a heterogeneous protein population with reduced activity due to restriction of substrate access to the active site. Methods based on chemical modifications are now available where MNP can be linked to a protein molecule via a single specific amino acid (such as N- or C- termini), thus avoiding reduction in activity due to the free access of the substrate to the active site. Moreover, site-directed immobilization also avoids modifying catalytic residues. One such common method involves using Alkyne-Azide Click chemistry as both groups are absent in proteins.
Germany, the birthplace of decaffeinated coffee, is home to several decaffeination plants, including the world's largest, Coffein Compagnie. Over half of the decaf coffee sold in the US first travels from the tropics to Germany for caffeine removal before making its way to American consumers. Coffee manufacturers recover the caffeine and resell it for use in soft drinks and over-the-counter caffeine tablets. The efficiency and selectivity of caffeine removal depend on the decaffeination method used. Water-based processes and supercritical carbon dioxide extraction are generally more selective, as they remove caffeine while preserving a larger proportion of volatile flavor compounds compared to some organic solvent methods. Extraction of caffeine from coffee, to produce caffeine and decaffeinated coffee, can be performed using various solvents. Following are main methods:
Diagenesis () is the process of physical and chemical changes in sediments first caused by water-rock interactions, microbial activity, and compaction after their deposition. Increased pressure and temperature only start to play a role as sediments become buried much deeper in the Earth's crust. In the early stages, the transformation of poorly consolidated sediments into sedimentary rock (lithification) is simply accompanied by a reduction in porosity and water expulsion (clay sediments), while their main mineralogical assemblages remain unaltered. As the rock is carried deeper by further deposition above, its organic content is progressively transformed into kerogens and bitumens. The process of diagenesis excludes surface alteration (weathering) and deep metamorphism. There is no sharp boundary between diagenesis and metamorphism, but the latter occurs at higher temperatures and pressures. Hydrothermal solutions, meteoric groundwater, rock porosity, permeability, dissolution/precipitation reactions, and time are all influential factors. After deposition, sediments are compacted as they are buried beneath successive layers of sediment and cemented by minerals that precipitate from solution. Grains of sediment, rock fragments and fossils can be replaced by other minerals (e.g. calcite, siderite, pyrite or marcasite) during diagenesis. Porosity usually decreases during diagenesis, except in rare cases such as dissolution of minerals and dolomitization.
Sources: en.wikipedia.org
== Collaboration == Tecemotide was developed – until Clinical trial phase II – by the Canadian biotech company Biomira Inc., which changed its company name to Oncothyreon Inc. in 2007. Oncothyreon is now located in Seattle, Washington, and it changed its name to SGEN after a merger and acquisition in March 2018. In 2001, Merck KGaA, of Darmstadt, Germany, entered into a collaboration and supply agreement with Biomira. In 2007, Merck KGaA acquired the exclusive worldwide marketing rights from Biomira, and Merck KGaA has since then been entirely responsible for the further clinical development of tecemotide. In 2008, Merck KGaA acquired the manufacturing rights for tecemotide from Oncothyreon. In 2011, Ono Pharmaceutical Company, of Japan, acquired a co-development and co-marketing license for tecemotide in Japan; Ono paid Merck KGaA 5 million euros.
must sum to 1). The alternative notation also makes it easier to understand the sub-models of the GTR model, which simply correspond to cases where exchangeability and/or equilibrium base frequency parameters are constrained to take on equal values. A number of specific sub-models have been named, largely based on their original publications:
=== Monocyte activation test === The monocyte activation test (MAT) uses the monocytes in human blood in vitro to detect pyrogens. It was added to the European Pharmacopoeia in 2010 and accepted by the FDA in 2012.
create eicosanoids hormones act on thermoregulatory center of hypothalamus to produce fever increase mating behaviors in goldfish cause the uterus to contract and/or to relax prevent gastrointestinal tract from self-digesting, contributing to its mucosal defence in multifactorial way.
=== Treatment === The development of the science of microsurgery over the last 40 years has provided several treatment options for a traumatic amputation, depending on the patient's specific trauma and clinical situation:
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.